Contributing Member of the Healthcare Councils

Names and details of certain GLG News authors are available only to GLG Clients and Council Members. GLG News authors are subject-matter experts within the GLG Councils and are available for expert consulting - by phone, in-person, or written analysis. To find out how to become a GLG client or Council Member, click here.

GLG News by this Author

Analyses are solely the work of the authors and have not been edited or endorsed by GLG.

GLG News is now G+ Insights

G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.

Will the new premium IntraOcular Lenses (IOLs) demand too much brainpower?

November 22, 2011

Humans have been on Earth for long enough to evolve neurosensory systems that have assured our survival. However, replacing the natural eye lens with an artificial, multifocal lens optic presents a perceptual challenge to our brain that it may not be able to accept. This insight will look at how the brain attempts to compensate for distortions in its perception, a process known as neuroadaptation, and whether or not we can justify the use of these devices.

Lens Refilling to Restore Accommodation-Too Good to be True?

March 5, 2009

Analysis of:Lens refilling to restore accommodation | www.sciencedirect.com

The article written by Nishi et al. in the Journal of Cataract and Refractive Surgery describes methodology that may (with emphasis on "may") create better methods of using liquid polymers in refilling the crystalline lens capsular bag as a substitute to rigid intraocular lens implants following cataract surgery. The concept is intriguing, but the science is lacking. What differentiates these researchers work from existing, is that they feel they have achieved better technologies that could advance the science. Realizing a liquid replacement for the human lens is an exciting concept. The hurdles that are positioned in translating that concept into a workable prototype are however, still looming large. undefined

Solx, Inc. is Acquired by Occulogix, Inc.

August 7, 2006

Analysis of:OccuLogix, SOLX enter definitive merger agreement | www.ophthalmologytimes.com

August 1st-OccuLogix Inc., of Toronto, Canada announced that it has signed a definitive merger agreement to purchase SOLX Inc. of Boston, Massachusetts. Solx, Inc. is an early-stage start-up that has struggled to develop an Infrared Laser and Gold Microshunt implantable device for the treatment of glaucoma. What is the implication of this acquisition?

Occulogix, Inc. which has failed to receive FDA approval for its plasmapheresis device for the treatment of Age-Related Macular Degeneration is acquiring Solx is an effort to diversify it's portfolio. It now has two non-approved modalities in two different areas of ophthalmology.

The Importance of a Preventative Vaccine for Shingles

August 2, 2006

Analysis of:FDA approves Zostavax, Merck's new vaccine for preventing shingles in adults 60 and older | www.therapeuticsdaily.com

Shingles is not just an annoying disease of the elderly, it is a significant debillitating process that results in pain, severe morbidity, and mortality. Twenty percent of adults will develop the disease. To date, there have been no effective treatments for "curing" shingles. Presently the only available oral antiviral therapies are Acyclovir (Zovirax, Merck) and related drugs, famciclovir and valacyclovir. These antiviral medications are most effective when started within 72 hours after the onset of the rash, and can at best, only lessen the duration of the disease. It cannot prevent it's onset, skin manifestations or pain. The development of a proven vaccine preventative for the herpes zoster virus is welcomed news to the millions of adults who are at risk of developing this disease.

Vision Care's Implantable Miniature Telescope Approval Delayed

July 20, 2006

Analysis of:Panel Meeting Summary - July 14, 2006 Meeting of the Ophthalmic Devices Panel | www.fda.gov

The FDA Ophthalmic Devices Advisory Committee just reviewed VisionCare’s Pre-Market Approval application (PMA) for the Implantable Miniature Telescope (IMT). The PMA application included the required one-year efficacy and two-year safety data from the IMT002 trial. It was the advisory committee’s recommendation that the device not be approved at this time. The committee was concerned about data regarding the long-term rate of corneal endothelial cell loss, despite significant gains in visual acuity and the improvement in quality of patients who were enrolled in the IMT002 trial.

Page : 11 to 5 of 5

Subscribe to Updates

By RSS